XTL Biopharmaceuticals Ltd. — Company profile
Healthcare · Biotechnology · Israel
Last price 1.61 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company’s lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
Details
| Name | XTL Biopharmaceuticals Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 5 |
| Founded | 1993 |
| Ipo Date | 2005-09-01 |
| Ceo | Noam Band |
| Country | Israel |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US98386D4060 |
| Cusip | 98386D406 |
| Cik | 0001023549 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Noam Band | Chief Executive Officer and Director |
| Segal Niv CPA | Chief Financial Officer |
Contact
| Address | 85 Medinat Hayehudim St., Herzliya, 4676670, Israel |
| Phone | 972 5 4228 8897 |
| Website | https://www.xtlbio.com |